Maze Therapeutics, Inc.MAZE stock score: 34/100

$32.43 · +3.94% · Scored Nov 19, 2026

Technical
49
Fundamental
30
News
—

The reading

Maze Therapeutics (MAZE) scores 34 out of 100, which reads bearish, higher than 9% of Healthcare stocks and 10% of the 4,118 US stocks we score.

The composite weights fundamentals 80% and technicals 20%: fundamentals read 30, technicals 49.

Among the fundamentals, Quick Ratio at 100 and Price Target at 100 score highest, while Earnings Growth (Annual) at 0 weighs the most against it.

On the daily chart, trend-following indicators average 46 and contrarian oscillators 53.

Since Aug 23, 2026 the composite has ranged from 34 to 50, and it is down 15 points over the period.

About Maze Therapeutics

Maze Therapeutics (MAZE) is a clinical-stage biotechnology company that develops oral small-molecule medicines for kidney and metabolic diseases, using human genetic data to choose drug targets. Its lead program, MZE829, is an oral inhibitor of the APOL1 protein being developed for APOL1-mediated kidney disease, a genetic form of chronic kidney disease that is more common among people of recent African ancestry. MZE829 has shown reductions in protein levels in the urine in a Phase two trial, and the company is preparing for later-stage studies. Its second program, MZE782, blocks the SLC6A19 transporter, which moves amino acids from the gut and kidney into the blood. Maze is testing MZE782 in phenylketonuria, an inherited disorder in which the amino acid phenylalanine builds up, and plans to study it in chronic kidney disease. The company has no approved products and funds its research mainly with cash raised from investors.

Maze faces competition from Vertex Pharmaceuticals, which is developing its own APOL1 inhibitor, and in phenylketonuria from BioMarin Pharmaceutical and PTC Therapeutics. Its edge rests on its genetics-driven approach to target selection, oral drugs that could treat broad patient groups and early clinical evidence in a disease with no approved targeted therapy. Investors who follow MAZE stock tend to watch further data from MZE829 and the design and start of a pivotal trial. Results from the MZE782 trial in phenylketonuria are closely followed. Feedback from regulators, cash runway, partnerships and the progress of Vertex’s competing program are other factors.

What’s driving the score

The strongest and weakest of the scorers that count toward MAZE’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.

Fundamental

30

Pulling it up

  • Quick ratio measures a company's ability to meet short-term obligations with liquid assets.

  • Price target score compares the current stock price to analyst consensus targets.

  • Current assets divided by current liabilities: the ability to pay short-term bills.

Holding it back

32 weighted scorers; 7 had no data today and are left out rather than counted as zero.

Technical · daily

50

Pulling it up

  • Where the close sits against its 200-day EMA.

  • Ichimoku Cloud is a comprehensive indicator showing support/resistance, trend direction, and momentum.

  • Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.

Holding it back

  • Parabolic SAR (Stop and Reverse) provides trailing stop levels that follow price trends.

  • Simple Moving Average (10-period) smooths price action over 10 periods.

  • Simple Moving Average (5-period) tracks the average price over the last 5 periods.

62 weighted scorers; 3 had no data today and are left out rather than counted as zero.

Technical score by timeframe

ChartScoreWeight
Hourly441
Daily503
Weekly512

Composite score, last 90 days

05010034Aug 23, 2026Nov 19, 2026Aug 23, 2026: 49Aug 24, 2026: 48Aug 25, 2026: 50Aug 26, 2026: 48Aug 27, 2026: 44Aug 28, 2026: 44Aug 29, 2026: 44Aug 30, 2026: 44Aug 31, 2026: 42Sep 1, 2026: 42Sep 2, 2026: 43Sep 3, 2026: 40Sep 4, 2026: 40Sep 5, 2026: 42Sep 6, 2026: 42Sep 7, 2026: 42Sep 8, 2026: 43Sep 9, 2026: 39Sep 10, 2026: 36Sep 11, 2026: 37Sep 12, 2026: 37Sep 13, 2026: 37Sep 14, 2026: 36Sep 15, 2026: 36Sep 16, 2026: 34Sep 17, 2026: 35Sep 18, 2026: 35Sep 19, 2026: 34Sep 20, 2026: 34Sep 21, 2026: 35Sep 22, 2026: 44Sep 23, 2026: 43Sep 24, 2026: 41Sep 25, 2026: 39Sep 26, 2026: 40Sep 27, 2026: 40Sep 28, 2026: 41Sep 29, 2026: 43Sep 30, 2026: 43Oct 1, 2026: 41Oct 2, 2026: 40Oct 3, 2026: 40Oct 4, 2026: 40Oct 5, 2026: 39Oct 6, 2026: 40Oct 7, 2026: 39Oct 8, 2026: 38Oct 9, 2026: 42Oct 10, 2026: 42Oct 11, 2026: 42Oct 12, 2026: 42Oct 13, 2026: 41Oct 14, 2026: 39Oct 15, 2026: 42Oct 16, 2026: 44Oct 17, 2026: 43Oct 18, 2026: 43Oct 19, 2026: 45Oct 20, 2026: 47Oct 21, 2026: 48Oct 22, 2026: 47Oct 23, 2026: 46Oct 24, 2026: 46Oct 25, 2026: 46Oct 26, 2026: 46Oct 27, 2026: 46Oct 28, 2026: 46Oct 29, 2026: 47Oct 30, 2026: 45Nov 1, 2026: 44Nov 2, 2026: 44Nov 3, 2026: 46Nov 4, 2026: 48Nov 5, 2026: 47Nov 6, 2026: 48Nov 7, 2026: 48Nov 8, 2026: 48Nov 10, 2026: 48Nov 11, 2026: 49Nov 12, 2026: 36Nov 13, 2026: 36Nov 14, 2026: 36Nov 15, 2026: 36Nov 16, 2026: 35Nov 17, 2026: 35Nov 18, 2026: 34Nov 19, 2026: 34
Show the daily numbers
DateComposite
Nov 19, 202634
Nov 18, 202634
Nov 17, 202635
Nov 16, 202635
Nov 15, 202636
Nov 14, 202636
Nov 13, 202636
Nov 12, 202636
Nov 11, 202649
Nov 10, 202648
Nov 8, 202648
Nov 7, 202648
Nov 6, 202648
Nov 5, 202647
Nov 4, 202648
Nov 3, 202646
Nov 2, 202644
Nov 1, 202644
Oct 30, 202645
Oct 29, 202647
Oct 28, 202646
Oct 27, 202646
Oct 26, 202646
Oct 25, 202646
Oct 24, 202646
Oct 23, 202646
Oct 22, 202647
Oct 21, 202648
Oct 20, 202647
Oct 19, 202645
Oct 18, 202643
Oct 17, 202643
Oct 16, 202644
Oct 15, 202642
Oct 14, 202639
Oct 13, 202641
Oct 12, 202642
Oct 11, 202642
Oct 10, 202642
Oct 9, 202642
Oct 8, 202638
Oct 7, 202639
Oct 6, 202640
Oct 5, 202639
Oct 4, 202640
Oct 3, 202640
Oct 2, 202640
Oct 1, 202641
Sep 30, 202643
Sep 29, 202643
Sep 28, 202641
Sep 27, 202640
Sep 26, 202640
Sep 25, 202639
Sep 24, 202641
Sep 23, 202643
Sep 22, 202644
Sep 21, 202635
Sep 20, 202634
Sep 19, 202634
Sep 18, 202635
Sep 17, 202635
Sep 16, 202634
Sep 15, 202636
Sep 14, 202636
Sep 13, 202637
Sep 12, 202637
Sep 11, 202637
Sep 10, 202636
Sep 9, 202639
Sep 8, 202643
Sep 7, 202642
Sep 6, 202642
Sep 5, 202642
Sep 4, 202640
Sep 3, 202640
Sep 2, 202643
Sep 1, 202642
Aug 31, 202642
Aug 30, 202644
Aug 29, 202644
Aug 28, 202644
Aug 27, 202644
Aug 26, 202648
Aug 25, 202650
Aug 24, 202648
Aug 23, 202649

Key facts

Market cap
$1.8B
Sector
Healthcare
Industry
Biotechnology
Beta
—
Risk grade (1–10)
8
Next earnings
Nov 9, 2026

Questions

What is MAZE's stock rating today?

MAZE scores 34/100 (Bearish) as of Nov 19, 2026: technical 49, fundamental 30. Scores are recomputed every night.

What does Maze Therapeutics do?

Maze Therapeutics (MAZE) is a clinical-stage biotechnology company that develops oral small-molecule medicines for kidney and metabolic diseases, using human genetic data to choose drug targets. Its lead program, MZE829, is an oral inhibitor of the APOL1 protein being developed for APOL1-mediated kidney disease, a genetic form of chronic kidney disease that is more common among people of recent African ancestry.

Is MAZE stock a buy?

The score is not a buy or sell recommendation. A 34 says the technical and fundamental signals we measure lean bearish today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.

How is the MAZE score calculated?

94 weighted scorers feed it today: 32 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 3 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.

Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.

Embed this score

A badge for a blog post, newsletter or README. It updates every night and links back here. More badges

MAZE stock score

HTML

<a href="https://stocksscores.com/stocks/maze/"><img src="https://stocksscores.com/stocks/maze/badge.svg" alt="MAZE stock score" height="20"></a>

Markdown

[![MAZE stock score](https://stocksscores.com/stocks/maze/badge.svg)](https://stocksscores.com/stocks/maze/)